Streetbeat News

Products Services

CGRN

Capstone Green Energy Corporation (CGRN) has secured an order for an 800kW biogas-fueled microturbine energy solution in Spain through its distributor Micropower Europe S.L. The unit will operate on landfill gas and is expected to be commissioned in October 2023.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:55 pm

IRTC

iRhythm Technologies (NASDAQ:IRTC) presented four studies at the Heart Rhythm Society's annual meeting, demonstrating the effectiveness of its Zio XT long-term ambulatory cardiac monitoring device in increasing diagnostic yield and improving diagnostic accuracy of ventricular arrhythmias. The studies highlight the value of iRhythm's Zio products and services in detecting life-threatening ventricular arrhythmias and preventing adverse health outcomes.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:54 pm

CMND

Clearmind Medicine has announced its first US site for a Phase I/IIa clinical trial evaluating CMND-100 in patients with alcohol use disorder.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:54 pm

AKBA

Akebia Therapeutics (NASDAQ: AKBA) has received UK MHRA approval for Vafseo, an oral treatment for symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. The approval is based on data from a comprehensive development program, including the global Phase 3 clinical program of vadadustat.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:54 pm

CLBT

Cellebrite DI Ltd. (NASDAQ:CLBT) has announced a significant agreement to deploy its digital intelligence software solutions, including cryptocurrency transaction data and insights, for a major Latin American country's federal forces. The deal increases the customer's annual spending with Cellebrite more than ten-fold.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:50 pm

ANIX

Anixa Biosciences has announced the treatment of the second patient in its ongoing Phase 1 clinical trial for ovarian cancer CAR-T therapy, in partnership with Moffitt Cancer Center. The trial aims to evaluate safety, determine the maximum tolerated dose, and preliminarily assess clinical activity.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:48 pm

KOPN

Kopin Corporation (NASDAQ:KOPN) has executed partner agreements for redundant and new OLED deposition capabilities to support the U.S. Department of Defense and NATO-friendly locations. The agreements also bring more OLED packaging and testing processes in-house at Kopin and provide access to a broader set of OLED displays and advanced technologies.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:46 pm

HEPA

Hepion Pharmaceuticals' stock is soaring after announcing positive results from its Phase 2 ALTITUDE-NASH trial, which met its primary endpoint and demonstrated improved liver function in subjects with stage 3 or greater fibrosis. All secondary endpoints were also met.

Portfolio Pulse from Adam Eckert

May 22, 2023 | 12:45 pm

ABVC

ABVC BioPharma's Vitargus Phase II study received ethical approval from the St. Vincent's Hospital Melbourne Human Research Ethics Committee. The study aims to demonstrate the safety and efficacy of Vitargus for the treatment of uncomplicated retinal detachment, and will be conducted in Australia and Thailand.

Portfolio Pulse from Happy Mohamed

May 22, 2023 | 12:43 pm

LIFE

aTyr Pharma will present new data on its lead therapeutic candidate, efzofitimod, at the American Thoracic Society 2023 International Conference. The data includes advancements in the understanding of efzofitimod's mechanism of action and exposure-response from a Phase 1b/2a study in pulmonary sarcoidosis patients.

Portfolio Pulse from Happy Mohamed

May 22, 2023 | 12:39 pm